Clinical data and state rules are separate facts. Both are shown; neither is a decision.
Strong inducer of CYP and UGT enzymes, so psilocin levels could fall in theory; narrow therapeutic range.
No pharmacology properties of concern are listed for this record.
No provision names this medication or its class.
Colorado · checked 2026-09-30No provision names this medication or its class.
Oregon · checked 2026-09-30New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.
New Mexico · checked 2026-09-30This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.